JP2022519930A5 - - Google Patents
Info
- Publication number
- JP2022519930A5 JP2022519930A5 JP2021557396A JP2021557396A JP2022519930A5 JP 2022519930 A5 JP2022519930 A5 JP 2022519930A5 JP 2021557396 A JP2021557396 A JP 2021557396A JP 2021557396 A JP2021557396 A JP 2021557396A JP 2022519930 A5 JP2022519930 A5 JP 2022519930A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- composition according
- chemotherapeutic agent
- doxorubicin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825017P | 2019-03-27 | 2019-03-27 | |
| US62/825,017 | 2019-03-27 | ||
| PCT/US2020/025532 WO2020198705A1 (en) | 2019-03-27 | 2020-03-27 | Combinations useful in a method for treating sarcoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519930A JP2022519930A (ja) | 2022-03-25 |
| JP2022519930A5 true JP2022519930A5 (https=) | 2023-04-04 |
| JP7602481B2 JP7602481B2 (ja) | 2024-12-18 |
Family
ID=72609016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557396A Active JP7602481B2 (ja) | 2019-03-27 | 2020-03-27 | 肉腫を治療する方法に有用な組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220152024A1 (https=) |
| EP (1) | EP3947379A4 (https=) |
| JP (1) | JP7602481B2 (https=) |
| CN (1) | CN114096537B (https=) |
| AU (1) | AU2020248103A1 (https=) |
| BR (1) | BR112021019170A2 (https=) |
| CA (1) | CA3134648A1 (https=) |
| EA (1) | EA202192349A1 (https=) |
| IL (1) | IL286647A (https=) |
| MX (1) | MX2021011688A (https=) |
| WO (1) | WO2020198705A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (https=) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| WO2008075330A1 (en) * | 2006-12-20 | 2008-06-26 | J-C Health Care Ltd. | Method for administration of pegylated liposomal doxorubicin |
| NZ746607A (en) * | 2012-11-21 | 2019-11-29 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| EP3836932A2 (en) * | 2018-08-17 | 2021-06-23 | PTC Therapeutics, Inc. | Method for treating pancreatic cancer |
| US20220185795A1 (en) * | 2019-03-11 | 2022-06-16 | Ptc Therapeutics, Inc. | Compound form having enhanced bioavailability and formulations thereof |
-
2020
- 2020-03-27 BR BR112021019170A patent/BR112021019170A2/pt not_active Application Discontinuation
- 2020-03-27 CA CA3134648A patent/CA3134648A1/en active Pending
- 2020-03-27 AU AU2020248103A patent/AU2020248103A1/en not_active Abandoned
- 2020-03-27 EP EP20776386.3A patent/EP3947379A4/en not_active Withdrawn
- 2020-03-27 EA EA202192349A patent/EA202192349A1/ru unknown
- 2020-03-27 MX MX2021011688A patent/MX2021011688A/es unknown
- 2020-03-27 JP JP2021557396A patent/JP7602481B2/ja active Active
- 2020-03-27 CN CN202080039624.8A patent/CN114096537B/zh active Active
- 2020-03-27 US US17/441,355 patent/US20220152024A1/en not_active Abandoned
- 2020-03-27 WO PCT/US2020/025532 patent/WO2020198705A1/en not_active Ceased
-
2021
- 2021-09-23 IL IL286647A patent/IL286647A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2757373C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2024133475A5 (https=) | ||
| JP2022520061A5 (https=) | ||
| EA037152B1 (ru) | Способ лечения рака | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| WO2004081012A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| AU2010235917A1 (en) | Combination of organic compounds | |
| JP2022519930A5 (https=) | ||
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| KR20220124739A (ko) | 암의 치료를 위한 병용 요법 | |
| EP1757283B1 (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| JP2020176071A (ja) | 血液がんの新規治療法及び新規治療剤 | |
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP2025511402A5 (https=) | ||
| US20220339162A1 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors | |
| JP2024518426A5 (https=) | ||
| EP3010508A1 (en) | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy | |
| CN112533604A (zh) | 用于治疗癌症的组合疗法 | |
| AU2024231699A1 (en) | Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy | |
| EP1203585A1 (en) | Anti-ischemic agent | |
| EP4676478A1 (en) | Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy | |
| JP6239745B2 (ja) | がんの処置のための、ｒｏ５５０３７８１及びカペシタビンの組み合わせ | |
| JP2022552336A (ja) | 造血器悪性腫瘍を治療するための併用療法 |